WO2007038073A3 - Mutations et polymorphismes de l’hdac11 - Google Patents

Mutations et polymorphismes de l’hdac11 Download PDF

Info

Publication number
WO2007038073A3
WO2007038073A3 PCT/US2006/036421 US2006036421W WO2007038073A3 WO 2007038073 A3 WO2007038073 A3 WO 2007038073A3 US 2006036421 W US2006036421 W US 2006036421W WO 2007038073 A3 WO2007038073 A3 WO 2007038073A3
Authority
WO
WIPO (PCT)
Prior art keywords
hdac11
mutations
mutant
polymorphisms
various aspects
Prior art date
Application number
PCT/US2006/036421
Other languages
English (en)
Other versions
WO2007038073A2 (fr
Inventor
Kenneth Wayne Culver
Jian Zhu
Stan Lilleberg
Original Assignee
Novartis Ag
Novartis Pharma Gmbh
Kenneth Wayne Culver
Jian Zhu
Stan Lilleberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Novartis Pharma Gmbh, Kenneth Wayne Culver, Jian Zhu, Stan Lilleberg filed Critical Novartis Ag
Publication of WO2007038073A2 publication Critical patent/WO2007038073A2/fr
Publication of WO2007038073A3 publication Critical patent/WO2007038073A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01098—Histone deacetylase (3.5.1.98), i.e. sirtuin deacetylase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne, globalement, le criblage analytique d’échantillons de tissus in vitro et, particulièrement, des aspects de polymorphismes génétiques et de mutations du gène HDAC11. L’invention concerne de nouveaux SNP et mutations d’HDAC11, utiles dans le diagnostic et le traitement de sujets en présentant le besoin. Par conséquent, les différents aspects de l’invention concernent des polynucléotides codant les mutations d’HDAC11 de l'invention, des vecteurs d’expression codant les polypeptides mutants d’HDAC11 de l’invention et des organismes exprimant les polynucléotides mutants et polymorphiques de l’HDAC (11) et/ou des polypeptides mutants/polymorphiques d’HDAC11 de l’invention. Les différents aspects de l’invention concernent en outre des kits et des procédés de diagnostic/théranostic utilisant les mutations et les polymorphismes d’HDAC11 de cette invention en vue d’identifier des individus prédisposés à des maladies ou de classifier des individus en fonction de leur capacité de réponse aux médicaments, aux effets secondaires ou à une posologie optimale.
PCT/US2006/036421 2005-09-22 2006-09-20 Mutations et polymorphismes de l’hdac11 WO2007038073A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71938405P 2005-09-22 2005-09-22
US60/719,384 2005-09-22

Publications (2)

Publication Number Publication Date
WO2007038073A2 WO2007038073A2 (fr) 2007-04-05
WO2007038073A3 true WO2007038073A3 (fr) 2007-06-07

Family

ID=37744153

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/036421 WO2007038073A2 (fr) 2005-09-22 2006-09-20 Mutations et polymorphismes de l’hdac11

Country Status (1)

Country Link
WO (1) WO2007038073A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014096386A1 (fr) * 2012-12-20 2014-06-26 Deutsches Krebsforschungszentrum Anticorps anti-hdac11
WO2018075959A1 (fr) 2016-10-20 2018-04-26 Forma Therapeutics, Inc. Procédés utilisant des inhibiteurs de hdac11
US11535607B2 (en) 2018-04-20 2022-12-27 Valo Health, Inc. Isoindolines as HDAC inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022577A2 (fr) * 2000-09-01 2002-03-21 Novartis Ag Inhibiteurs de desacetylase
WO2005071079A1 (fr) * 2004-01-21 2005-08-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Inhibiteurs de hdac 11 mammifere utiles dans le traitement de troubles a mediation par hdac 11

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022577A2 (fr) * 2000-09-01 2002-03-21 Novartis Ag Inhibiteurs de desacetylase
WO2005071079A1 (fr) * 2004-01-21 2005-08-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Inhibiteurs de hdac 11 mammifere utiles dans le traitement de troubles a mediation par hdac 11

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GAO LIN ET AL: "Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family", 12 July 2002, JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, PAGE(S) 25748-25755, ISSN: 0021-9258, XP002324623 *

Also Published As

Publication number Publication date
WO2007038073A2 (fr) 2007-04-05

Similar Documents

Publication Publication Date Title
WO2007016532A3 (fr) Mutations et polymorphismes de hdac4
WO2006130527A3 (fr) Mutations et polymorphismes de recepteur du facteur de croissance 1 des fibroblastes
WO2006127861A3 (fr) Diagnostic de maladies et d'etats pathologiques par l'analyse d'echantillons biologiques traites par voie histopathologique a l'aide de preparations tissulaires liquides
WO2002086448A3 (fr) Detection de l'instabilite des microsatellites et son utilisation dans le diagnostic des tumeurs
WO2005114190A3 (fr) Procedes pour identifier des marqueurs biologiques
WO2006105252A3 (fr) Diagnostic de la bronchopneumopathie chronique obstructive, et suivi de la therapie associee par analyse de l'expression de cellules sanguines
NZ600235A (en) Methods and compositions for the assessment of drug response
WO2006073682A3 (fr) Test diagnostique
HK1093674A1 (en) Anti-april monoclonal antibody and its use for the treatment of an immune related disease or cancer
EP2287340A3 (fr) Procédé de diagnostic et traitement d'une maladie mentale
EP2293074A3 (fr) Procédé pour le diagnostic de maladies neuro-dégénératives
WO2006110478A3 (fr) Mutations et polymorphismes du recepteur du facteur de croissance epidermique
WO2009065132A8 (fr) Prédiction et diagnostic de patients atteints d'une maladie auto-immune
WO2008060777A3 (fr) Utilisation de la technique elisa pour rechercher vegf
NZ596614A (en) Diagnosis and treatment of alzheimer's disease
WO2008122670A3 (fr) Gène tnfrsf10b de susceptibilité au diabète chez l'homme
EP2503338A3 (fr) CD73 comme biomarqueur pour surveiller le développement de maladies et évaluer l'efficacité des thérapies
WO2007022041A3 (fr) Mutations et polymorphismes de l'hdac3
ATE432997T1 (de) Therapieüberwachung für tumoren unter benutzung acc133 mrna
BR0111473A (pt) Métodos para triar um indivìduo quanto a uma doença de armazenagem de glicogênio, para triar um indivìduo quanto à doença de pompe, para monitorar a condição clìnica de um indivìduo com doença de pompe, para estimar a eficácia de um regime terapêutico em um indivìduo com doença de pompe e para determinar a concentração de um oligossacarìdeo em uma amostra biológica
WO2005118403A3 (fr) Procedes pour detecter l'expression genique dans des cellules du sang peripherique et utilisations de ces procedes
WO2007030455A3 (fr) Mutations et polymorphismes de hdac10
AU2006228990A8 (en) A method of diagnosis and treatment and agents useful for same
WO2007038073A3 (fr) Mutations et polymorphismes de l’hdac11
WO2007030454A3 (fr) Mutations et polymorphismes de hdac9

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06814913

Country of ref document: EP

Kind code of ref document: A2